PBKM – EKF interview

PBKM – EKF interview

In this interview, CEO Jakub Baran discusses PBKM’s profile as a leading European stem cell bank. He outlines the recent voluntary exchange offer launched by Vita34 and PBKM’s strategy after the merger. He then explains the effect of COVID-19 on PBKM’s offline distribution channels and provides an update on the developments within PBKM’s therapies and drug manufacturing business.


You may also be interested in these:

Healthcare

Herantis Pharma – executive interview

Investment Companies

Finsbury Growth & Income Trust – equity proposition